Get 20% Off All Market Studies With Code ONLINE20 – Anticipate Tariff Impacts, Market Disruptors, and Long-Term Growth Trends
What Is the Forecasted Market Size of the Autoimmune Monoclonal Antibody Market by 2029?
The autoimmune monoclonal antibody market size has grown strongly in recent years. It will grow from $65.83 billion in 2024 to $70.86 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing prevalence of autoimmune diseases, growing use of biologics in treatment, rising awareness of targeted therapies, early approvals of monoclonal antibody drugs, and expansion of healthcare access in developed countries.
The autoimmune monoclonal antibody market size is expected to see strong growth in the next few years. It will grow to $96.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising adoption of biosimilars, expanding clinical trials in autoimmune therapy, growing geriatric population, and rising prevalence of chronic immune disorders. Major trends in the forecast period include advancement in antibody engineering, development of bispecific antibodies, growing use of artificial intelligence in drug discovery, integration of genomics in treatment planning, and novel drug delivery systems.
Claim your free report sample now:
What Are the Major Drivers Influencing the Autoimmune Monoclonal Antibody Market?
The increasing demand for biologics is expected to propel the growth of the autoimmune monoclonal antibody market going forward. Biologics refers to a category of medical products derived from living organisms or their components, used in the treatment, prevention, or diagnosis of diseases. The increasing demand for biologics is primarily driven by their ability to effectively treat complex diseases, such as cancer, autoimmune disorders, and genetic conditions, where traditional therapies may be less effective. Autoimmune monoclonal antibody enhances biologic therapies by providing targeted immune modulation, making them effective for managing overactive immune responses. They reduce the need for broad immunosuppressants by offering precise treatment, improving patient outcomes and minimizing side effects. For instance, in June 2024, according to the Cardinal Health Inc., a US-based healthcare company, there are 40 Food and Drug Administration (FDA) approved biosimilar products in 2023, 25 of which are commercially available in the US market, an increase from 33 biosimilar products in 2022. Therefore, the increasing the demand for biologics is driving the growth of the autoimmune monoclonal antibody market.
Which Are the Leading Segments in the Autoimmune Monoclonal Antibody Market by Revenue?
The autoimmune monoclonal antibody market covered in this report is segmented –
1) By Type: Immunoglobulin G Monoclonal Antibodies, Immunoglobulin M Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Route Of Administration: Subcutaneous, Intravenous, Intramuscular
3) By Application: Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, Psoriasis, Inflammatory Bowel Disease
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Research Institutions
Subsegments:
1) By Immunoglobulin G (IgG) Monoclonal Antibodies: Immunoglobulin G1 (IgG1), Immunoglobulin G2 (IgG2), Immunoglobulin G3 (IgG3), Immunoglobulin G4 (IgG4)
2) By Immunoglobulin M (IgM) Monoclonal Antibodies: Pentameric Immunoglobulin M (IgM), Hexameric Immunoglobulin M (IgM)
3) By Chimeric Monoclonal Antibodies: Murine Variable Region + Human Constant Region, Humanized Variable Region + Murine Constant Region
4) By Fully Human Monoclonal Antibodies: Phage Display-Derived, Transgenic Mouse-Derived, Fully Human Hybridoma-Derived
Which Trends Are Positively Affecting the Autoimmune Monoclonal Antibody Market Expansion?
Major companies operating in autoimmune monoclonal antibody are focusing on developing innovative solutions, such as biosimilar development to enhance safety, efficacy, and quality. Biosimilar development is the process of creating highly similar, safe, and effective biological products to existing approved biologics, using advanced biotechnology, rigorous analytical testing, and clinical studies to demonstrate comparable quality, efficacy, and safety for regulatory approval. For instance, in February 2025, Biocon Biologics Limited, an India-based biopharmaceutical company, launched YESINTEK, a biosimilar that treats autoimmune diseases such as Crohn’s disease, ulcerative colitis, and psoriasis, by targeting and inhibiting the activity of interleukin-12 and interleukin-23 to reduce inflammation and regulate the immune response. Yesintek by mimicking the reference product stelara, supports long-term disease management while increasing patient access to biologic therapies.
Who Are the Leading Players in the Autoimmune Monoclonal Antibody Market?
Major companies operating in the autoimmune monoclonal antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Genmab A/S, Zymeworks Inc., Xencor Inc., Immutep Limited, Cue Biopharma Inc., Santa Ana Bio Inc.
Get the full autoimmune monoclonal antibody market report here:
What Are the Opportunities and Challenges for Autoimmune Monoclonal Antibody Market Across Regions?
North America was the largest region in the autoimmune monoclonal antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autoimmune monoclonal antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment